SHELLEY WIGLER: Open Payments
NPI 1962111245 · NEWTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,171 in 116 payments from 23 companies in 2025. Trend: 2023 $240 · 2024 $1,135 · 2025 $2,171
Food & beverage: $2,171
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $317 |
| AstraZeneca Pharmaceuticals LP | 14 | $246 |
| Novo Nordisk Inc | 12 | $233 |
| Sumitomo Pharma America, Inc. | 9 | $194 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $130 |
| Lilly USA, LLC | 7 | $127 |
| Astellas Pharma US Inc | 5 | $104 |
| Neurocrine BioSciences, Inc. | 4 | $90 |
| Axsome Therapeutics, Inc. | 3 | $82 |
| Almatica Pharma LLC | 5 | $79 |
Products named: GEMTESA, UBRELVY, Kerendia, VRAYLAR, MOUNJARO, REXULTI, AIRSUPRA, Veozah.
Industry payments across PA — which companies pay providers there.
